On June 25, 2020 Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, reported that Dr. Cheng Liu, President and Chief Executive Officer, is scheduled to participate at Oppenheimer’s Private Life Sciences Company Call Series on Monday, June 29, 2020 (Press release, Eureka Therapeutics, JUN 25, 2020, View Source [SID1234561488]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Liu will be presenting the use of Eureka’s novel antibody-TCR receptor (ARTEMIS T cell) that has been engineered with a proprietary human TCR-mimic antibody to target the alpha fetoprotein (AFP)-peptide/HLA-A2 complex on HCC cancer cells.
Presentation Details
Title:
ARTEMIS Antibody TCR T Cell Therapy for Solid Tumors
Speaker:
Dr. Cheng Liu, President and CEO
Date:
Monday, June 29, 2020
Time:
3:00 p.m. EST
Location: